Sanofi India Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sanofi India Ltd is ₹ 3402 as of 05 May 15:30 . The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 .The P/E Ratio of Vaishali Pharma Ltd is 0 as of December 2023 . The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 .The Market Cap of Vaishali Pharma Ltd is ₹ 0 crore as of December 2023 . The revenue of Sanofi India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Vaishali Pharma Ltd for the Dec '25 is ₹ 25.54 crore as compare to the Sep '25 revenue of ₹ 34.29 crore. This represent the decline of -25.52% The ebitda of Sanofi India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Vaishali Pharma Ltd for the Dec '25 is ₹ 2.45 crore as compare to the Sep '25 ebitda of ₹ 2.23 crore. This represent the growth of 9.87% The net profit of Sanofi India Ltd changed from ₹ 136.6 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of -100.00% The net profit of Vaishali Pharma Ltd changed from ₹ 1.28 crore to ₹ 1.3 crore over 3 quarters. This represents a CAGR of 2.09% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% The dividend payout of Vaishali Pharma Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% .

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Sanofi India Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Sanofi India Ltd or Vaishali Pharma Ltd?

Market cap of Sanofi India Ltd is 8,111 Cr while Market cap of Vaishali Pharma Ltd is 100 Cr

What are the key factors driving the stock performance of Sanofi India Ltd and Vaishali Pharma Ltd?

The stock performance of Sanofi India Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sanofi India Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the Sanofi India Ltd stock price is INR ₹3522.25. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.73.

How do dividend payouts of Sanofi India Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Sanofi India Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.